Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1990 Sep-Oct;63(5):435–443.

Blood transfusion effects in kidney transplantation.

C B Carpenter 1
PMCID: PMC2589367  PMID: 2149898

Abstract

Within the three decades since the beginnings of the field of clinical renal transplantation there have been four phases in blood transfusion policies, swinging from liberal transfusions to avoidance of transfusions, followed by a repeat cycle of deliberate transfusions and at present turning back to abstinence again. Because of improving skills at the prevention and treatment of rejections, the beneficial effects of random transfusions in the transplant population as a whole is marginal. This comes at a time when community fears of blood-borne infections and the prospects of supporting red cell production by the use of EPO have emerged as new factors in blood banking. Observations on patients at risk for graft loss, namely those having rejection episodes, indicate that a beneficial blood transfusion effect still exists, however. Future application of deliberate HLA antigen exposure in conjunction with novel immunological manipulations may provide a more effective avenue to tolerance induction. The use of blood transfusions matched for one HLA-DR antigen with the recipient has produced major benefits in preliminary trials and represents one starting point in this direction.

Full text

PDF
435

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson C. B., Sicard G. A., Etheredge E. E. Pretreatment of renal allograft recipients with azathioprine and donor-specific blood products. Surgery. 1982 Aug;92(2):315–321. [PubMed] [Google Scholar]
  2. Claas F. H., Gijbels Y., van der Velden-de Munck J., van Rood J. J. Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life. Science. 1988 Sep 30;241(4874):1815–1817. doi: 10.1126/science.3051377. [DOI] [PubMed] [Google Scholar]
  3. Dallman M. J., Wood K. J., Morris P. J. Recombinant interleukin-2 (IL-2) can reverse the blood transfusion effect. Transplant Proc. 1989 Feb;21(1 Pt 1):1165–1167. [PubMed] [Google Scholar]
  4. Fischer E., Lenhard V., Seifert P., Kluge A., Johannsen R. Blood transfusion-induced suppression of cellular immunity in man. Hum Immunol. 1980 Oct;1(3):187–194. doi: 10.1016/0198-8859(80)90013-0. [DOI] [PubMed] [Google Scholar]
  5. Fuller T. C., Delmonico F. L., Cosimi B., Huggins C. E., King M., Russell P. S. Impact of blood transfusion on renal transplantation. Ann Surg. 1978 Feb;187(2):211–218. doi: 10.1097/00000658-197802000-00020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Glass N. R., Miller D. T., Sollinger H. W., Belzer F. O. Comparative analysis of the DST and Imuran-plus-DST protocols for live donor renal transplantation. Transplantation. 1983 Dec;36(6):636–641. doi: 10.1097/00007890-198336060-00009. [DOI] [PubMed] [Google Scholar]
  7. Goulmy E., Stijnen T., Groenewoud A. F., Persijn G. G., Blokland E., Pool J., Paul L. C., van Rood J. J. Renal transplant patients monitored by the cell-mediated lympholysis assay. Evaluation of its clinical value. Transplantation. 1989 Oct;48(4):559–563. doi: 10.1097/00007890-198910000-00004. [DOI] [PubMed] [Google Scholar]
  8. Herzog W. R., Zanker B., Irschick E., Huber C., Franz H. E., Wagner H., Kabelitz D. Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft. Transplantation. 1987 Mar;43(3):384–389. doi: 10.1097/00007890-198703000-00013. [DOI] [PubMed] [Google Scholar]
  9. Iwaki Y., Cecka J. M., Terasaki P. I. The transfusion effect in cadaver kidney transplants--yes or no. Transplantation. 1990 Jan;49(1):56–59. doi: 10.1097/00007890-199001000-00012. [DOI] [PubMed] [Google Scholar]
  10. Kawamura T., Sakagami K., Haisa M., Morisaki F., Takasu S., Inagaki M., Oiwa T., Orita K. Induction of antiidiotypic antibodies by donor-specific blood transfusions. Establishment of a human-mouse hybridoma secreting the MLR-inhibiting factor. Transplantation. 1989 Sep;48(3):459–463. doi: 10.1097/00007890-198909000-00022. [DOI] [PubMed] [Google Scholar]
  11. Lagaaij E. L., Hennemann I. P., Ruigrok M., de Haan M. W., Persijn G. G., Termijtelen A., Hendricks G. F., Weimar W., Claas F. H., van Rood J. J. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med. 1989 Sep 14;321(11):701–705. doi: 10.1056/NEJM198909143211101. [DOI] [PubMed] [Google Scholar]
  12. Lundgren G., Groth C. G., Albrechtsen D., Brynger H., Flatmark A., Frödin L., Gäbel H., Husberg B., Klintmalm G., Maurer W. HLA-matching and pretransplant blood transfusions in cadaveric renal transplantation--a changing picture with cyclosporin. Lancet. 1986 Jul 12;2(8498):66–69. doi: 10.1016/s0140-6736(86)91608-9. [DOI] [PubMed] [Google Scholar]
  13. Matas A. J., Simmons R. L., Buselmeier T. J., Najarian J. S., Kjellstrand C. M. Lethal complications of bilateral nephrectomy and splenectomy in hemodialyzed patients. Am J Surg. 1975 Jun;129(6):616–620. doi: 10.1016/0002-9610(75)90332-3. [DOI] [PubMed] [Google Scholar]
  14. Morimoto C., Letvin N. L., Boyd A. W., Hagan M., Brown H. M., Kornacki M. M., Schlossman S. F. The isolation and characterization of the human helper inducer T cell subset. J Immunol. 1985 Jun;134(6):3762–3769. [PubMed] [Google Scholar]
  15. Opelz G. Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplantation. 1985 Sep;40(3):240–243. doi: 10.1097/00007890-198509000-00003. [DOI] [PubMed] [Google Scholar]
  16. Opelz G., Graver B., Mickey M. R., Terasaki P. I. Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation. 1981 Sep;32(3):177–183. doi: 10.1097/00007890-198109000-00002. [DOI] [PubMed] [Google Scholar]
  17. Opelz G. Improved kidney graft survival in nontransfused recipients. Transplant Proc. 1987 Feb;19(1 Pt 1):149–152. [PubMed] [Google Scholar]
  18. Opelz G., Sengar D. P., Mickey M. R., Terasaki P. I. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973 Mar;5(1):253–259. [PubMed] [Google Scholar]
  19. Opelz G., Terasaki P. I. Importance of preoperative (not peroperative) transfusions for cadaver kidney transplants. Transplantation. 1981 Feb;31(2):106–108. doi: 10.1097/00007890-198102000-00002. [DOI] [PubMed] [Google Scholar]
  20. Opelz G., Terasaki P. I. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med. 1978 Oct 12;299(15):799–803. doi: 10.1056/NEJM197810122991503. [DOI] [PubMed] [Google Scholar]
  21. Parfrey P. S., Forbes R. D., Hutchinson T. A., Beaudoin J. G., Dauphinee W. D., Hollomby D. J., Guttmann R. D. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation. 1984 May;37(5):461–466. doi: 10.1097/00007890-198405000-00008. [DOI] [PubMed] [Google Scholar]
  22. Phelan D. L., Rodey G. E., Anderson C. B. The development and specificity of antiidiotypic antibodies in renal transplant recipients receiving single-donor blood transfusions. Transplantation. 1989 Jul;48(1):57–60. doi: 10.1097/00007890-198907000-00013. [DOI] [PubMed] [Google Scholar]
  23. Sakane T., Green I. Specificity and suppressor function of human T cells responsive to autologous non-T cells. J Immunol. 1979 Aug;123(2):584–589. [PubMed] [Google Scholar]
  24. Salvatierra O., Jr, Vincenti F., Amend W., Potter D., Iwaki Y., Opelz G., Terasaki P., Duca R., Cochrum K., Hanes D. Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg. 1980;192(4):543–552. doi: 10.1097/00000658-198010000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Schriemer P. A., Longnecker D. E., Mintz P. D. The possible immunosuppressive effects of perioperative blood transfusion in cancer patients. Anesthesiology. 1988 Mar;68(3):422–428. doi: 10.1097/00000542-198803000-00017. [DOI] [PubMed] [Google Scholar]
  26. Thomas J., Thomas F., Lee H. M. Why do HLA-nonidentical renal allografts survive 10 years or more? Transplant Proc. 1977 Mar;9(1):85–89. [PubMed] [Google Scholar]
  27. Toyotome A., Terasaki P. I., Salvatierra O., Starzl T., Hakala T., Kahan B., Diethelm A., Najarian J., Wolf J., Butt K. Early graft function. Clin Transpl. 1987:435–452. [PubMed] [Google Scholar]
  28. Wu H. S., Little A. G. Perioperative blood transfusions and cancer recurrence. J Clin Oncol. 1988 Aug;6(8):1348–1354. doi: 10.1200/JCO.1988.6.8.1348. [DOI] [PubMed] [Google Scholar]
  29. van Rood J. J., Claas F. H. The influence of allogeneic cells on the human T and B cell repertoire. Science. 1990 Jun 15;248(4961):1388–1393. doi: 10.1126/science.1972596. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES